Incorrect username and/or password, please try again or click to reset.

Xigris 5 mg and 20 mg recall due to risk/benefit concerns

2014-12-17 14:56:43 (10 year(s) ago)

Summary

(Eli Lilly) Recall following clinical trial findings showing lack of efficacy and risk/benefit concerns – class 1 action now. (EL (14)A/15)

Read full MHRA article

Respond to this alert